



SIGNIA THERAPEUTICS ANNOUNCES RECRUITMENT OF CEO

Signia Therapeutics announces the nomination of Dr. Philippe Personne as CEO, effective as of 1st of October.

Dr. Personne graduated with a Doctorate in Pharmacy from Université de Lyon and cumulates more than 25 years of experience in the healthcare industry, mostly in the field of pharmaceuticals and medical devices. He held several management positions, with responsibility of affiliates, business units and profit centers. Dr. Personne brings Signia Therapeutics his wide experience and expertise in the pharmaceutical industry environment, especially in terms of strategic organization, business development and overall corporate and operational management.

Signia Therapeutics' breakthrough drug discovery technology is based on a specific comparative analysis between transcriptomic signatures of pathologies obtained from clinical patient samples and drug transcriptomic signatures characterized in innovative physiological models. Continuing successes of Signia Therapeutics in drug repurposing in infectiology and other medical areas, Dr. Personne's mission is to drive the Company to upper levels and significantly increase the pipeline of antimicrobial molecules. The next stages of corporate development will include a new round of capital raise, reinforcement of the operational team, continuation of product development by expanding Signia Therapeutics' proprietary database, pipeline and first-in-class drug discovery platform, offering a systematic approach for rationalized drug repositioning. He will also define strategy in contracting partnerships with other pharma companies to redirect highly valued compounds that have never been brought to the market, in new therapeutic areas, and obviously generate a substantial return on investment by identifying new market opportunities

About Signia Therapeutics

Signia Therapeutics current assets comprises a molecule pipeline including eight repurposed marketed drugs as new validated antivirals and protected by international patents, an extensive library of viruses, several *ex vivo* and *in vivo* models of infection, BSL-2/BSL-3 facilities and other equipment, representing altogether a very cost efficient and low risk development strategy. An ongoing phase 2b clinical trial (FLUNEXT TRIAL PHRC #15-0442 - ClinicalTrials.gov identifier NCT03212716) started in January 2018 in order to evaluate one of Signia Therapeutics' anti-influenza compound. This national multicentre double randomized clinical trial aims at assessing the effect of repurposed diltiazem, a calcium modulator with newly identified anti-influenza activity, in combination with standard antiviral oseltamivir (Tamiflu®) for the treatment of severe influenza infections. The FLUNEXT trial aims at enrolling 300 severe Flu patients in 10 intensive care units, with final results expected in 2019.

Signia Therapeutics is in a leadership position with its first-in-class drug discovery platform to identify & repurpose rapidly, efficiently, in a systematic manner and at low cost, drugs for new therapeutic indications with unmet medical needs. Please visit www.signiatherapeutics.com for more information.

Contacts:

Michel Cousineau, President
+33 6 70314670 / +1 418-575-9709
michel.cousineau@signiatherapeutics.com

Philippe Personne, CEO
+33 6 47343488
philippe.personne@signiatherapeutics.com